title: [Intervention treatment of hepatocellular carcinoma with 125I-lipiodol plus chemotherapeutic drugs and self body hairs: a report of 56 cases].
abstract: OBJECTIVE
  To study the therapeutic effects on primary hepatic cancer of intervention treatment with a preparation consisting of 125I-iodinated lipiodol ultrafluid (LUF) plus self body hairs and cell-cycle nonspecific chemotherapeutic agents.
  
  
  METHODS
  The treatment was given to 56 patients with primary hepatic cancer. CT, US, DSA, serum AFP determination, and urine radioactivity were carried out before and after treatment.
  
  
  RESULTS
  The preparation was found to be held up in the end arteries supplying the tumor for a considerable length of time without passing through blood capillaries into the general circulation. It helped keep the chemotherapeutic drugs and internal radiation staying at the tumor site. The side effects of this treatment were tolerable. No rejection reaction was observed. In thirty six of the 56 patients (64.3%), the tumor reduced by 50%-70% in diameter, and in the remaining 20 patients(35.7%) the reduction in tumor diameter was less than 50% or not at all. The clinical manifestations, liver functions and serum AFP level improved in all cases. The survival rate in 6, 12, 24 and 36 months was 100%, 82.1%, 63.1% and 55.6%, respectively.
  
  
  CONCLUSIONS
  The new intervention treatment for primary liver cancer herein described is easy to perform and can significantly improve survival and quality of life.
authors.affiliation: Second Affiliated Hospital, Nanjing Medical University, Nanjing 210011, China.
authors.forename: C
authors.initials: C
authors.lastname: Xu
authors.forename: J
authors.initials: J
authors.lastname: Wang
authors.forename: S
authors.initials: S
authors.lastname: Zheng
mesh_terms: D000328:Adult; D000368:Aged; D000376:Agmatine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001158:Arteries / Q000648:ultrastructure; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality; D016461:Chemoembolization, Therapeutic; D002945:Cisplatin / Q000627:therapeutic use*; D004337:Drug Carriers; D016503:Drug Delivery Systems; D005260:Female; D006197:Hair; D006801:Humans; D007457:Iodine Radioisotopes; D007459:Iodized Oil / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000627:therapeutic use; D013386:Succinates / Q000627:therapeutic use; D015996:Survival Rate; D016896:Treatment Outcome; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D004337:Drug Carriers; D007457:Iodine Radioisotopes; C068976:MMC complex; D013386:Succinates; D000509:alpha-Fetoproteins; D016685:Mitomycin; D000376:Agmatine; D007459:Iodized Oil; D002945:Cisplatin